targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01812369 | Active, not recruiting | 3 | 2013-02-01 | null | null | null | Phase III+ | Phase II+ | 1,056,561,954,893 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03869190 | Recruiting | 1 | 2019-06-01 | null | null | null | null | null | 1,176,821,039,654 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00268450 | Terminated | 2 | 2005-09-21 | Terminated | stopped | null | null | Phase II+ | 1,245,540,517,965 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT03924895 | Recruiting | 3 | 2019-07-24 | null | null | null | Phase III+ | Phase II+ | 1,254,130,451,405 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00021099 | Completed | 2 | 2001-06-01 | null | null | null | null | Phase II+ | 1,340,029,798,279 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00933374 | Terminated | 2 | 2009-07-01 | Terminated | stopped | null | null | Phase II+ | 1,468,878,816,446 | delayed recruitment | Phase 2 | 31/07/2009 | Terminated | 18/03/2015 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005831 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 1,511,828,488,645 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00055601 | Completed | 2 | 2002-12-01 | null | null | null | null | Phase II+ | 1,546,188,226,810 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |